Side effect of deferiprone as iron chelator in patient with thalassemia
نویسندگان
چکیده
منابع مشابه
Effect of Oral Iron Chelator Deferiprone on Skeletal Radiography of Thalassemia Major Patients
Regular blood transfusion along with iron chelation therapy is a supportive treatment for thalassemia major. Chelation therapy too has its side effects. The most common adverse effects associated with administration of deferiprone are agranulocytosis, neutropenia and arthralgia, primarily, of the large joints. Objective : The study was undertaken to examine the effect of deferiprone on the larg...
متن کاملChelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
BACKGROUND AND OBJECTIVE Excessive hemosiderosis is the main reason for the multi-organ failure observed in multitransfused patients. Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients. DESIGN AND METHODS A group of 11 thalass...
متن کاملIron chelator drugs in thalassemia,a review article
Abstract Thalassemia syndromes are the most common inherited hemoglobinopathies in the world characterized by various degrees of defective production of the alpha or beta globin chains. Impairment in alpha chain or beta chain synthesis leads to alpha thalassemia and beta thalassemia syndromes respectively. Iran is one of the countries located on the thalassemia belt therefore this disease is ...
متن کاملEffect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
The standard iron-chelator deferoxamine is known to prevent the growth of coagulase-negative staphylococci (CoNS) which are major pathogens in iron-overloaded patients. However, we found that deferoxamine rather promotes the growth of coagulase-positive Staphylococcus aureus. Accordingly, we tested whether deferiprone, a new clinically-available iron-chelator, can prevent the growth of S. aureu...
متن کاملEffect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial
Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Paediatrica Indonesiana
سال: 2018
ISSN: 2338-476X,0030-9311
DOI: 10.14238/pi57.6.2017.329-36